PTT-936
PreclinicalSmall molecule
PTT-936 is one of 17 small molecule programs targeting Locally Advanced or Metastatic Solid Tumors. It is currently in Preclinical.
1
Indications
1
Total Trials
1
Active Trials
16
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
37 competitors in Locally Advanced or Metastatic Solid Tumors
#DrugCompanyPhaseTrials
1Keytruda
Merck & Co.Phase 2
Stivarga
BayerPhase 2
Afinitor
NovartisPhase 2
OPDUALAG
Bristol-Myers SquibbPhase 2
Budigalimab
AbbViePhase 1
BL-M08D1
SSichuan Baili Pharmaceutical Co., Ltd.
Phase 1
SYHA1813
SShanghai Runshi Pharmaceutical Technology Co., Ltd
Phase 2
BC3195
BBiocity Biopharmaceutics Co., Ltd.
Phase 2
ASKB589
AAskGene Pharma, Inc.
Phase 2
KB707
KKrystal Biotech, Inc.
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for PTT-936. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- PPyrotech Therapeutics, Inc.